Advertisement
HORSHAM, PA (March 29,2004) – Centocor, Inc. has signed a definitive agreement with Wyeth for the acquisition of Wyeth's biopharmaceutical manufacturing facility in St. Louis, Centocor said last week.Purchase of the site is expected to allow Centocor to increase clinical material production for products currently in its pipeline. With the acquisition, Centocor said it now will own and operate four manufacturing facilities on two continents.

The St. Louis facility was originally constructed in 1986 and has had recombinant biologics manufacturing on site since 1987. The facility, according to Centocor, is approved by the U.S. Food & Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA).

Centocor, a wholly owned subsidiary of Johnson & Johnson, is a biomedicines company involved in the research and development of treatments for a wide range of Immune-Mediated Inflammatory Disorders (I.M.I.D.), such as arthritis and inflammatory skin diseases, and for cancer. Its products are developed primarily through monoclonalantibody technology.

Advertisement
Advertisement